A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.

One of the self-proclaimed frontrunners in the pembrolizumab biosimilar race, Formycon, has initiated the first clinical trial for its FYB206 candidate. Meanwhile, Celltrion submits a Phase III trial application to the FDA, expecting “limitless” sales potential for its CT-P51 version.

With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.

While investigating the potential of the Japanese market for its denosumab, Gedeon Richter is preparing for several regulatory filings, including its tocilizumab biosimilar.